Table 1.
Virus | circRNA | Methods | Ribosome binding | Cellular location | Function and mechanism | Reference(s) |
---|---|---|---|---|---|---|
EBV | circEBNA_U, circRPMS1_E4_E3a | circRNAome | IRES | Cytoplasm and nucleus | Fundamental processes during latent infection | [27] |
EBV | circBART_1, circBART_2 | RNA sequencing | ND | Cytoplasm and nucleus | Tumor virus pathogenesis | [59] |
EBV | circrpms1 | RNA sequencing | ND | Cytoplasm and n nucleus | EBV-associated gastric carcinoma and RNA-protein interactions | [28,60] |
EBV | circlmp2 | RNA sequencing | ND | Cytoplasm and nucleus | Inducing and maintaining stemness | [22] |
EBV | circbhlf1 | circRNAome | ND | Nucleus | Encoded 200 amino acid peptide | [27] |
KSHV | circvIRF4, circPAN/K7.3 | Biochemistry methods | ND | Cytoplasm, nucleus | Incorporation into KSHV virions | [26] |
KSHV | circvIRF4, circPAN/K7.3 | RNA sequencing | ND | Cytoplasm, nucleus and polysome | Tumor virus pathogenesis | [59] |
KSHV | Kcirc54, Kcirc55, Kcirc97, | Microarrays | ND | ND | ND | [61] |
HPV16 | circE7 | RNA sequencing | ND | Cytoplasm | Tumor virus pathogenesis | [62] |
HBV | HBV_circ_1 | Sanger sequencing | ND | Cytoplasm | Stimulating tumour growth | [63] |
MDV | 289 MDV circRNAs | inverse PCRs and existing RNA sequencing data | ND | ND | ND | [64] |
MERS-CoV, SARS-CoV-1/2 | 3437 circRNAs | RNA sequencing | ND | ND | ND | [65] |
GCRV-873 | 32 GCRV-derived circRNAs | CircRNA-sequencing | ND | ND | Interaction with miRNAs | [66] |
MCPyV | circALTO1, circALTO2 | RNA sequencing | ND | Cytoplasm | Enhancing transcription of host genes | [67] |
Abbreviations: EBV, Epstein-Barr virus; KSHV, Kaposi sarcoma-associated herpesvirus; ND, not determined.